{
  "newsletter_id": "lai_weekly_v5_2025_12_23",
  "client_id": "lai_weekly_v5",
  "generated_at": "2025-12-23T07:32:23.113756Z",
  "period": {
    "start_date": "2025-12-23",
    "end_date": "2025-12-23"
  },
  "metrics": {
    "total_items": 3,
    "items_by_section": {
      "regulatory_updates": 2,
      "partnerships_deals": 1,
      "clinical_updates": 0,
      "others": 0
    },
    "unique_sources": 2,
    "key_entities": {
      "companies": [],
      "technologies": [],
      "trademarks": [
        "PharmaShell速",
        "UZEDY速"
      ]
    }
  },
  "sections": [
    {
      "section_id": "regulatory_updates",
      "title": "Regulatory Updates",
      "items": [
        {
          "item_id": "press_corporate__medincell_20251223_516562",
          "title": "Teva Pharmaceuticals has submitted a New Drug Application to the U.S. FDA for Olanzapine Extended-Re",
          "score": 10.2,
          "published_at": "2025-12-23",
          "source_url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf",
          "entities": {
            "companies": [],
            "technologies": [],
            "trademarks": []
          }
        },
        {
          "item_id": "press_corporate__medincell_20251223_c147c4",
          "title": "Teva is preparing to submit a New Drug Application (NDA) to the US FDA for its long-acting injectabl",
          "score": 10.2,
          "published_at": "2025-12-23",
          "source_url": "https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf",
          "entities": {
            "companies": [],
            "technologies": [],
            "trademarks": [
              "UZEDY速"
            ]
          }
        }
      ]
    },
    {
      "section_id": "partnerships_deals",
      "title": "Partnerships & Deals",
      "items": [
        {
          "item_id": "press_corporate__nanexa_20251223_6f822c",
          "title": "Nanexa and Moderna have entered into a license and option agreement for the development of up to fiv",
          "score": 9.8,
          "published_at": "2025-12-23",
          "source_url": "https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/",
          "entities": {
            "companies": [],
            "technologies": [],
            "trademarks": [
              "PharmaShell速"
            ]
          }
        }
      ]
    }
  ],
  "bedrock_calls": {
    "tldr_generation": {
      "status": "success"
    },
    "introduction_generation": {
      "status": "success"
    }
  }
}